Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TYMP | P19971 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | IDE | P14735 | 1/20 | 0.34 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27905866 | 0.80 | CYP1A2 (0.48) | NPC1TYMPALDH1A1L3MBTL1KDM4E | |
| SCHEMBL27436337 | 0.80 | NPC1 (0.48) | NPC1TYMPALDH1A1L3MBTL1KDM4E | |
| SCHEMBL62885 | 0.75 | NPSR1 (0.50) | NPC1ALDH1A1POLBL3MBTL1KDM4E | |
| SCHEMBL29812111 | 0.74 | POLB (0.38) | TYMPALDH1A1POLBL3MBTL1KDM4E | |
| SCHEMBL28289948 | 0.74 | TYMP (0.36) | NPC1TYMPALDH1A1POLBL3MBTL1 | |
| SCHEMBL1396973 | 0.73 | POLB (0.41) | POLBRAB9AGAAMEN1KMT2A | |
| SCHEMBL9786590 | 0.73 | L3MBTL1 (0.48) | NPC1TYMPALDH1A1POLBL3MBTL1 | |
| SCHEMBL27625365 | 0.72 | JAK2 (0.53) | TYMPJAK2THRB | |
| SCHEMBL8545504 | 0.72 | HPGD (0.56) | NPC1ALDH1A1POLBL3MBTL1KDM4E | |
| SCHEMBL28177075 | 0.70 | POLB (0.42) | ALDH1A1POLBTDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119432830-A | Systems and methods for isolating mRNA | 苏州艾博生物科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-116064598-B | Nucleic acid vaccine for coronavirus | 苏州艾博生物科技有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117003658-A | Lipid Nanoparticle Compositions | 苏州艾博生物科技有限公司 | 2023-11-07 | — | — | CN | disclosed |
| CN-116472275-A | Lipid compounds and lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116332830-A | Lipid compounds and lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-114206827-B | Lipid nanoparticle compositions | 苏州艾博生物科技有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-116064598-A | Nucleic acid vaccine for coronavirus | 苏州艾博生物科技有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-6835726-B2 | Pyrimidine derivatives | AMGEN INC. | 2004-12-28 | — | — | US | disclosed |
| US-20040006068-A1 | Pyrimidine derivatives | TULARIK INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2002064096-A9 | METHODS OF USING PYRIMIDINE-BASED ANTIVIRAL AGENTS | TULARIK INC (US) | 2003-10-16 | — | — | WO | disclosed |
| EP-1056742-B1 | ANTI-VIRAL PYRIMIDINE DERIVATIVES | TULARIK INC (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20030130264-A1 | Methods of using pyrimidine-based antiviral agents | TULARIK INC. (US) | 2003-07-10 | — | — | US | disclosed |
| US-6528513-B2 | Viricides; especially cytomegalo virus | TULARIK INC | 2003-03-04 | — | — | US | disclosed |
| WO-2002064096-A2 | METHODS OF USING PYRIMIDINE-BASED ANTIVIRAL AGENTS | TULARIK INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| US-20010018436-A1 | Pyrimidine derivatives | TULARIK INC. | 2001-08-30 | — | — | US | disclosed |
| US-6200977-B1 | USEFUL IN TREATING AND SUPPRESSING HUMAN CYTOMEGALOVIRUS | TULARIK INC. | 2001-03-13 | — | — | US | disclosed |
| EP-1056742-A1 | ANTI-VIRAL PYRIMIDINE DERIVATIVES | TULARIK, INC. (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999041253-A1 | ANTI-VIRAL PYRIMIDINE DERIVATIVES | TULARIK INC. (US) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130264-A1 | Methods of using pyrimidine-based antiviral agents | TYMP, TYMS, NUDT1 | NPC1 2289/4885TYMP 1/4885ALDH1A1 2001/4885 |
| US-20010018436-A1 | Pyrimidine derivatives | TYMP, TYMS, UMPS | NPC1 2412/4885TYMP 1/4885ALDH1A1 2587/4885 |
| US-20040006068-A1 | Pyrimidine derivatives | TYMP, TYMS, UMPS | NPC1 2412/4885TYMP 1/4885ALDH1A1 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.